It is the first such approval for a diagnostic that combines next-generation sequencing and liquid biopsy in one test.
Two technologies—next-generation sequencing (NGS) and liquid biopsy—are combined in one diagnostic test to help guide treatment decisions for patients with a particularly deadly form of advanced lung cancer.
It is the first such approval for a diagnostic like this, the FDA said, calling it “a new era for mutation testing.”
The test is for patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in metastatic non–small cell lung cancer (NSCLC).
“In addition to benefitting from less invasive testing, patients are provided with a simultaneous mapping of multiple biomarkers of genomic alterations, rather than one biomarker at a time, which can translate to decreased wait times for starting treatment and provide insight into possible resistance mechanisms,” Tim Stenzel, MD, PhD, director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health, said in a statement.
The approval was granted to Guardant360CDx to provide information on multiple solid tumor biomarkers and to help identify EGFR mutations in patients who will benefit from treatment with osimertinib (Tagrisso), which is approved for a form of metastatic NSCLC.
Osimertinib was granted Breakthrough Therapy Designation from the FDA last month for EGFR-mutated NSCLC, following surgery for completely tumor resection. Likewise, the Guardant360 CDx assay was granted a Breakthrough Device Designation as well.
A liquid biopsy uses a blood sample to uncover genetic information about a tumor and can be used where standard tissue biopsies are not feasible, such as tumor location. The NGS technology in the assay uses high-throughput tumor profiling and can simultaneously detect mutations in 55 tumor genes, rather than 1 gene at a time.
The FDA also clarified when a biopsy should be performed.
“Genomic findings for other biomarkers evaluated are not validated for choosing a particular corresponding treatment with this approval,” the FDA said. “If the specific NSCLC mutations associated with today’s approval are not detected in the blood, then a tumor biopsy should be performed to determine if the NSCLC mutations are present.”
The Guardant assay was the second of 2 such approvals by the FDA last week. Earlier in the week, the FDA approved clonoSEQ, made by Adaptive Biotechnologies, for its third indication to detect minimal residual disease, this time in chronic lymphocytic leukemia.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More